Abstract: This disclosure provides compounds of Formula (1), compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by axonal degeneration.

Abstract: This application provides a signal processing method and a related apparatus. The method is applied to a network device and includes: receiving sounding signal information from user equipment, where the sounding signal information includes N pieces of sub-sounding signal information received by N antennas of the network device; performing first weighting processing on the sounding signal information based on a first matrix to determine first signal information; determining a channel weight of to-be-sent signal information based on the first signal information, and weighting the to-be-sent signal information based on the channel weight, to determine N pieces of second signal information; performing second weighting processing on the N pieces of second signal information based on a second matrix to obtain N pieces of third signal information, where the second matrix is an inverse matrix of the first matrix; and sending the corresponding third signal information using the N antennas.

Abstract: Provided are compounds of Formula (I) having activity as inhibitors of G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and uses and methods of treating certain disorders, such as cancer, including but not limited to lung, pancreatic and colorectal cancers.

Abstract: A method to generate hydrogen gas comprises circulating an electrolyte through an electrolyte circuit including an electrochemical cell comprising an anode and a cathode, wherein hydroxide ions in the electrolyte are oxidized at the anode to produce oxygen gas and water in the electrolyte is reduced at the cathode to produce hydrogen gas. The method further includes introducing an inert gas into the electrolyte circuit to dilute a gas phase of the electrolyte circuit.

Abstract: This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including uses in modulating SARM1 and treating various diseases and conditions, e.g., those caused by or associated with axonal degeneration.

Abstract: A display panel includes a pixel definition layer on a base substrate, having a plurality of first apertures extending there-through; a light emitting layer at least partially in the plurality of first apertures; an encapsulating layer on a side of the pixel definition layer and the light emitting layer away from the base substrate; a bank layer on a side of the encapsulating layer away from the base substrate, having a plurality of second apertures extending there-through; and a color conversion layer at least partially in the plurality of second apertures. The color conversion layer comprises a plurality of color conversion blocks. A minimum height of a bottom of the bank layer with respect to a surface of the base substrate is greater than a minimum height of a bottom of a respective color conversion block with respect to the surface of the base substrate.

Abstract: A vapor chamber is provided. The vapor chamber includes a first cover close to a heat source, and a second cover far from the heat source. The first cover and the second cover form a cavity, the cavity is divided into at least a first cavity and a second cavity, and the first cavity and the second cavity have different cross-sectional sizes. A first wick is disposed in the first cavity, and the first wick has one end connected to the first cover and the other end connected to the second cover. A second wick is disposed in the second cavity, and the second wick is parallel to the first cover. The first wick is connected to the second wick, and the first cavity communicates with the second cavity.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of a BCL-2 inhibitor; and optionally, a therapeutically effective amount of at least one other antineoplastic agent. Also disclosed are methods for treating a subject who has been diagnosed with a hematopoietic disorder using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia.

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein the variables are defined herein.

Abstract: The present disclosure relates to the field of heat dissipation technologies, and provides a Vapor Chamber (VC) and an electronic device. The VC includes a first housing and a second housing that are disposed opposite to each other. The first housing and the second housing form a closed chamber. The first housing includes a bottom wall for making contact with a heat source. The second housing has a top wall facing the bottom wall. A first capillary structure is disposed on the bottom wall. The first capillary structure comprises a heat source region capillary structure and a non-heat source region capillary structure. The heat source region capillary structure includes a plurality of convex capillary structures and/or a plurality of first concave capillary structures.

Abstract: The present application relates to a replicable RNA molecule and the use thereof. The replicable RNA molecule comprises, from the 5? end to the 3? end, a 5? cap, a 5? UTR, an open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3? UTR and a poly(A) tail, wherein the RNA replicase is capable of amplifying the replicable RNA molecule and is capable of amplifying an RNA molecule containing the sequence of interest and 3? UTR, wherein the RNA replicase is a nonstructural protein or a functional variant thereof derived from Mosso das Pedras virus (MDPV), Everglades virus (EVEV), Rio Negro virus (RNV), Mucambo virus (MUCV), Highlands J virus (HJV), Pixuna virus (PIXV), Trocara virus (TROV), Cabassou virus (CABV), Tonate virus (TONV), Bebaru virus (BEBV), Fort Morgan virus (FMV), Getah virus (GETV) or Ndumu virus (NDUV).

Abstract: The present disclosure provides a display panel and a display apparatus. The display panel includes: a substrate, including a plurality of sub-pixel regions; a plurality of light emitting devices, located on one side of the substrate and corresponding to the sub-pixel regions one by one; a first pixel definition layer, located on one side, facing away from the substrate, of the light emitting devices and including first opening regions corresponding to the sub-pixel regions one by one; a plurality of quantum dot layers, located on the side, facing away from the substrate, of the light emitting devices and located in at least part of the first opening regions; and a plurality of first refractive index patterns, located between the light emitting devices and the quantum dot layers, where a refractive index of each quantum dot layer is greater than that of each first refractive index pattern.

Abstract: Disclosed in the embodiments of the present application are a heat sink and an electronic device. The disclosed heat sink comprises a base, a condensation portion and an isolation portion, wherein the base is provided with an evaporation cavity, and a gaseous working medium output port and a liquid working medium backflow port, which are both in communication with the evaporation cavity; the isolation portion is provided with a gaseous working medium input channel; a first end portion of the gaseous working medium input channel is in communication with the gaseous working medium output port; the isolation portion is arranged in the condensation portion; a liquid working medium backflow channel is formed between the outer surface of the isolation portion and the inner wall of the condensation portion; and the isolation portion isolates the gaseous working medium output port from the liquid working medium backflow port.

Abstract: A display substrate includes a first base substrate; a reflective layer on the first base substrate; a color conversion layer on a side of the reflective layer away from the first base substrate; and a plurality of light sources in an inter-subpixel region and a color filter comprising a plurality of color filter blocks at least partially in a plurality of subpixel regions, respectively, on a side of the color conversion layer away from the reflective layer. One or more light sources of the plurality of light sources are in a first gap between two adjacent color filter blocks of the plurality of color filter blocks. An orthographic projection of the plurality of light sources and an orthographic projection of the color conversion layer on a plane perpendicular to a surface of the first base substrate and intersecting the plurality of light sources and the color conversion layer are non-overlapping.

Abstract: A display panel includes a first base substrate, a light-emitting device layer located on a side of the first base substrate, a color filter layer located on a side of the light-emitting device layer away from the first base substrate, a color conversion layer located between the light-emitting device layer and the color filter layer, a touch function layer located on a side of the color conversion layer away from the first base substrate and a light adjustment layer located on a side of the touch function layer away from the first base substrate. The light adjustment layer includes first particles and second particles. The first particles each include dye molecules. The second particles each have a hollow structure.

Abstract: A non-fungible token (NFT) game is provided that allows the players to create image NFTs from color pixel NFTs. The NFT game provides the tools for the players to mint different color pixel NFTs with different sizes different shapes, and different colors. The players may search for and may buy different color pixel NFTs. The players may sell the images they create and may buy images created by other players. The game provides a drawing pad and displays at least a subset of the color pixel NFTs that a player owns. The player may generate an image by moving the color pixel NFTs into the drawing pad. The player may mint an image NFT from the color pixel NFTs moved into the drawing pad. After the image NFT is minted, the color pixel NFTs used in drawing the image NFT are burned.